November 27, 2019

Video: Bioceros develops monoclonal antibodies as a division of Polpharma Biologics Group

Dr. Louis Boon, Chief Scientific Officer of Bioceros (division of Polpharma Biologics Group), talked about Bioceros CHOBC® own platform and explains how SPOT & SLIM technology boost specific productivity and make process more efficient. Speaking at BIO-Europe® 2019 in Hamburg, Dr. Boon cited two recent partnerships, one with Sandoz for commercialization of a Natalizumab biosimilar, […]

Read More

November 18, 2019

First subjects in ph III study with PB006 (proposed Biosimilar to Natalizumab) have been randomized.

Our phase III clinical trial (PB006-03-01) entered into the stage when first patients were treated with study medication. This study study is conducted in 7 countries in and outside Europe including Poland. First participants were included in the study at the clinical site in Katowice (Poland). The study, managed by Hendrik Wessels, Polpharma Biologics Clinical Development team, […]

Read More

September 3, 2019

Polpharma Biologics announces global commercialization deal for biosimilar natalizumab, a key multiple sclerosis medicine

Polpharma Biologics today announces that it has entered a global commercialization agreement with Sandoz AG for a natalizumab biosimilar. Under this agreement, Polpharma Biologics will be responsible for the development, manufacturing and supply of the collaboration biosimilar. “This important commercial agreement marks a significant milestone in Polpharma Biologic’s ongoing commitment to producing more affordable, high-quality biopharmaceuticals […]

Read More


For media inquiries, please contact:

Kamila Oliwa-Stasiak,

Senior Communication Specialist.